Effectiveness and Tolerability of the Single-Pill Combination of Bisoprolol and Perindopril in Patients with Arterial Hypertension and Stable Coronary Artery Disease in Daily Clinical Practice: The STYLE Study

Sergey A Boytsov, Yuri P Burtsev, Yunona V Khomitskaya, Yuri A Karpov, STYLE study investigators

Abstract

Introduction: Combination antihypertensive therapy is required by most patients to achieve guideline-recommended blood pressure (BP) goals. This study assessed the effectiveness and tolerability of bisoprolol/perindopril (Bis/Per) single-pill combination (SPC) in Russian patients with hypertension and coronary artery disease (CAD) treated in routine clinical practice.

Methods: STYLE (NCT03730116) was an open-label, uncontrolled, prospective observational study conducted in patients who were already receiving Bis/Per SPC, switched to SPC from Bis or Per monotherapy, or switched from a free combination of Bis and Per. Primary endpoint criteria were assessed at 1 and 3 months and included change in mean office systolic/diastolic blood pressure (SBP/DBP), proportion achieving target BP (< 140/90 mmHg), and measures of antianginal effectiveness.

Results: The full analysis set comprised 1892 subjects. Mean age was 61.9 ± 8.8 years, 53.2% were women, and mean durations of hypertension and CAD were 12.5 ± 7.9 and 7.2 ± 6.4 years, respectively. Mean SBP/DBP decreased by 22.3/11.0 mmHg and 31.5/15.9 mmHg at 1 and 3 months, respectively (P < 0.0001 vs baseline). Target BP was achieved by 49.2% and 86.7% of patients at 1 and 3 months, respectively. Reductions in mean number of angina attacks and nitrate consumption and improvements in heart rate were statistically significant. Treatment was well tolerated.

Conclusion: Treatment of patients with hypertension and CAD with Bis/Per SPC for 3 months was associated with significant decreases in SBP/DBP and a high proportion of patients achieving BP treatment goals. This was accompanied by an improvement in angina symptoms. Treatment was well tolerated in a broad patient population representative of those seen in everyday clinical practice.

Keywords: Angina; Arterial hypertension; Bisoprolol; Blood pressure; Coronary artery disease; Heart rate; Perindopril; Single-pill combination (SPC).

Figures

Fig. 1
Fig. 1
Change in mean blood pressure at visit 2 (1 month) and visit 3 (3 months) compared with visit 1 (inclusion visit). For both SBP and DBP, changes were statistically significant for visit 2 compared with visit 1 and for visit 3 compared with visit 1 (all P < 0.0001)
Fig. 2
Fig. 2
Proportion of subjects achieving blood pressure targets at visit 2 (1 month) and visit 3 (3 months)
Fig. 3
Fig. 3
Change in mean heart rate (HR) at visit 2 (1 month) and visit 3 (3 months) compared with visit 1 (inclusion visit)
Fig. 4
Fig. 4
Change in quality of life at visit 2 (1 month) and visit 3 (3 months) compared with visit 1 (inclusion visit). VAS visual analog scale

References

    1. GBD 2015 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1659–1724. doi: 10.1016/S0140-6736(16)31679-8.
    1. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317(2):165–182. doi: 10.1001/jama.2016.19043.
    1. Leon DA, Malyutina S, Kudryavtsev AV, et al. Dissecting hypertension in Russia: identifying aetiological and behavioural factors associated with treatment and control. Eur J Pub Health. 2018 doi: 10.1093/eurpub/cky212.876.
    1. Kontsevaya A, Kalinina A, Oganov R. Economic burden of cardiovascular diseases in the Russian Federation. Value Health Reg Issues. 2013;2(2):199–204. doi: 10.1016/j.vhri.2013.06.010.
    1. Rotar O, Konradi A, Tanicheva A, et al. May measurement month 2017 in Russia: hypertension treatment and control, Europe. Eur Heart J Suppl. 2019;21(Suppl D):D101–D103. doi: 10.1093/eurheartj/suz068.
    1. Shalnova SA, Drapkina OM. Contribution of the ESSE-RF study to preventive healthcare in Russia. Cardiovasc Therapy Prevent. 2020;19(3):2602. doi: 10.15829/1728-8800-2020-2602.
    1. Williams B, Mancia G, Spiering W. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.
    1. Kobalava ZD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russ J Cardiol. 2020;25(3):3786.
    1. Kotseva K, De Bacquer D, De Backer G, et al. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. Eur J Prev Cardiol. 2016; 23(18):2007–18.
    1. Fox KM, EURopean trial on reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study) Lancet. 2003;362(9386):782–788. doi: 10.1016/S0140-6736(03)14286-9.
    1. Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Fox KM. Perindopril and β-blocker for the prevention of cardiac events and mortality in stable coronary artery disease patients: a EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease (EUROPA) subanalysis. Am Heart J. 2015;170(6):1092–1098. doi: 10.1016/j.ahj.2015.08.018.
    1. Brugts JJ, Bertrand M, Remme W, et al. The treatment effect of an ACE-inhibitor based regimen with perindopril in relation to beta-blocker use in 29,463 patients with vascular disease: a combined analysis of individual data of ADVANCE, EUROPA and PROGRESS trials. Cardiovasc Drugs Ther. 2017;31(4):391–400. doi: 10.1007/s10557-017-6747-9.
    1. Kobalava Z, Khomitskaya Y, Kiyakbaev G, ATHENA trial investigators AchievemenT of target resting HEart rate on beta-blockers in patients with stable angiNA and hypertension (ATHENA) in routine clinical practice in Russia. Curr Med Res Opin. 2014;30(5):805–811. doi: 10.1185/03007995.2013.874993.
    1. Leonova MV, Steinberg LL, Belousov YB, et al. Results of pharmacoepidemiologic study of arterial hypertension Pifagor IV: physicians compliance. Russ J Cardiol. 2015;1(117):59–66. doi: 10.15829/1560-4071-2015-1-59-66.
    1. Girerd X, Radauceanu A, Achard JM, et al. Evaluation of patient compliance among hypertensive patients treated by specialists. Arch Mal Coeur Vaiss. 2001;94(8):839–842.
    1. R Core Team. R: a language and environment for statistical computing. 2013. R Foundation for Statistical Computing, Vienna, Austria. .
    1. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020; 41(3):407–7.
    1. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685–692. doi: 10.1016/j.amjcard.2011.10.025.
    1. Zugck C, Martinka P, Stöckl G. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice. Adv Ther. 2014;31(9):961–974. doi: 10.1007/s12325-014-0147-3.
    1. Steg PG, Ferrari R, Ford I, et al. Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. PLoS One. 2012;7(5):e36284.
    1. von Arnim T, The TIBBS Investigators Medical treatment to reduce total ischemic burden: total ischemic burden bisoprolol study (TIBBS), a multicenter trial comparing bisoprolol and nifedipine. J Am Coll Cardiol. 1995;25:231–238. doi: 10.1016/0735-1097(94)00345-Q.
    1. Daly CA, Clemens F, Sendon JL, et al. Inadequate control of heart rate in patients with stable angina: results from the European heart survey. Postgrad Med J. 2010;86:212–217. doi: 10.1136/pgmj.2009.084384.
    1. Brorsson B, Bernstein SJ, Brook RH, Werkö L. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002;87:140–145. doi: 10.1136/heart.87.2.140.
    1. Vautier S. Measuring change with multiple visual analog scales: application to tense arousal. Eur J Psychol Assess. 2011;27(2):111–120. doi: 10.1027/1015-5759/a000051.
    1. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71(6):1269–1324. doi: 10.1161/HYP.0000000000000066.
    1. Thomopoulos C, Katsimagklis G, Archontakis S, Skalis G, Makris T. Optimizing the management of uncontrolled hypertension: what do triple fixed-dose drug combinations add? Curr Vasc Pharmacol. 2017;16:61–65. doi: 10.2174/1570161115666170414115301.
    1. Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension. 2021;77:692–705. doi: 10.1161/HYPERTENSIONAHA.120.15781.
    1. Egan BM, Bandyopadhyay D, Shaftman SR, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124–1131. doi: 10.1161/HYPERTENSIONAHA.112.194167.
    1. Bahiru E, de Cates AN, Farr MR, et al. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Cochrane Database Syst Rev. 2017;3:009868.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit